ShadowBuys

SEC EDGAR · Company announcement

ICLR: 6-K company filing

Filed 6-K for an event or period dated 2026-09-30. Read the company report for its disclosures.

Follow ICLR
Became public
Oct 27, 2026, 5:05 PM EDT
Event / period date
Sep 30, 2026
Collected
Nov 7, 2026, 8:26 PM EST

Why this is connected

This filing identifies ICON PLC as the issuer of the security. The company's SEC identifier connects it to ICLR.

Source evidence

Read the source excerpt or record
iclr-20260930 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2026 Commission File Number: 333-08704 ICON plc (Translation of registrant's name into English) South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Ireland (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ ICON plc This report on Form 6-K is hereby incorporated by reference into the registration statements of ICON plc on Form S-8 (Registration Nos. 333-152802, 333-204153, 333-231527, 333-254891, 333-257578 and 333-282826) and on Form F-3 (Registration No. 333-278943), and this report on Form 6-K shall be deemed a part of each such registration statement from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished by ICON plc under the Securities Act of 1933 or the Securities Exchange Act of 1934. 1 GENERAL As used herein, “ICON plc”, “ICON”, "ICON Group", the “Company” and “we”, "our" or “us” refer to ICON public limited company and its consolidated subsidiaries, unless the context requires otherwise. Business ICON is a contract research organization (“CRO”), providing outsourced services on a global basis to pharmaceutical, biotechnology, medical device and government and public health organizations. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process, from compound selection to Phase I-IV clinical studies. O ur vision is to be the healthcare intellig

Congressional trading in ICLR

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.